Viridian Therapeutics Inc... (VRDN)
Viridian Therapeutics Statistics
Share Statistics
Viridian Therapeutics has 81.48M shares outstanding. The number of shares has increased by 27.67% in one year.
| Shares Outstanding | 81.48M |
| Shares Change (YoY) | 27.67% |
| Shares Change (QoQ) | 2.87% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 73.28M |
| Failed to Deliver (FTD) Shares | 9.31K |
| FTD / Avg. Volume | 0.94% |
Short Selling Information
The latest short interest is 11.63M, so 14.69% of the outstanding shares have been sold short.
| Short Interest | 11.63M |
| Short % of Shares Out | 14.69% |
| Short % of Float | 16.5% |
| Short Ratio (days to cover) | 5.85 |
Valuation Ratios
The PE ratio is -4.82 and the forward PE ratio is -4.55. Viridian Therapeutics's PEG ratio is 0.19.
| PE Ratio | -4.82 |
| Forward PE | -4.55 |
| PS Ratio | 4309.18 |
| Forward PS | 1 |
| PB Ratio | 1.94 |
| P/FCF Ratio | -5.59 |
| PEG Ratio | 0.19 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Viridian Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.43, with a Debt / Equity ratio of 0.03.
| Current Ratio | 15.43 |
| Quick Ratio | 15.43 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.08 |
| Debt / FCF | -0.09 |
| Interest Coverage | -98.17 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $2.11K |
| Profits Per Employee | $-1.89M |
| Employee Count | 143 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -19.43% in the last 52 weeks. The beta is 1.09, so Viridian Therapeutics's price volatility has been higher than the market average.
| Beta | 1.09 |
| 52-Week Price Change | -19.43% |
| 50-Day Moving Average | 16.47 |
| 200-Day Moving Average | 18.06 |
| Relative Strength Index (RSI) | 33.49 |
| Average Volume (20 Days) | 991.69K |
Income Statement
In the last 12 months, Viridian Therapeutics had revenue of 302K and earned -269.95M in profits. Earnings per share was -3.98.
| Revenue | 302K |
| Gross Profit | 302K |
| Operating Income | -299.04M |
| Net Income | -269.95M |
| EBITDA | -266.36M |
| EBIT | -266.9M |
| Earnings Per Share (EPS) | -3.98 |
Balance Sheet
The company has 99.59M in cash and 21.09M in debt, giving a net cash position of 78.5M.
| Cash & Cash Equivalents | 99.59M |
| Total Debt | 21.09M |
| Net Cash | 78.5M |
| Retained Earnings | -995.86M |
| Total Assets | 742.4M |
| Working Capital | 690.59M |
Cash Flow
In the last 12 months, operating cash flow was -232.32M and capital expenditures -511K, giving a free cash flow of -232.83M.
| Operating Cash Flow | -232.32M |
| Capital Expenditures | -511K |
| Free Cash Flow | -232.83M |
| FCF Per Share | -3.43 |
Margins
Gross margin is 100%, with operating and profit margins of -99018.21% and -89387.09%.
| Gross Margin | 100% |
| Operating Margin | -99018.21% |
| Pretax Margin | -89387.09% |
| Profit Margin | -89387.09% |
| EBITDA Margin | -88199.67% |
| EBIT Margin | -99018.21% |
| FCF Margin | -77096.03% |
Dividends & Yields
VRDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for VRDN is $34, which is 159.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $34 |
| Price Target Difference | 159.5% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Stock Splits
The last stock split was on Nov 13, 2020. It was a backward split with a ratio of 1:15.
| Last Split Date | Nov 13, 2020 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | 6.98 |
| Piotroski F-Score | 2 |